SCHEMBL4848564

SCHEMBL4848564

CCc1nc(C=Cc2cn(-c3ccccc3)nc2OCc2ccc(OCc3csc(N4CCCCC4)n3)c(OC)c2)cs1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 5/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
ALOX12 P18054 1/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DNM1L O00429 3/20 0.36
APP P05067 3/20 0.34
ERBB2 P04626 4/20 0.34
EPHA2 P29317 4/20 0.34
KDR P35968 3/20 0.34
EPHB4 P54760 3/20 0.34
KCNH2 Q12809 1/20 0.33
SCN9A Q15858 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4848560 1.00 F2RL3 (0.37) F2RL3MEN1KMT2AKDM4EALDH1A1
SCHEMBL4850595 1.00 F2RL3 (0.37) F2RL3MEN1KMT2AKDM4EALDH1A1
SCHEMBL4845922 0.87 MEN1 (0.40) F2RL3MEN1KMT2AKDM4EALDH1A1
SCHEMBL4850589 0.86 MEN1 (0.38) F2RL3MEN1KMT2AKDM4EALDH1A1
SCHEMBL4850653 0.86 MEN1 (0.38) F2RL3MEN1KMT2AKDM4EALDH1A1
SCHEMBL4846373 0.82 F2RL3 (0.38) F2RL3MEN1KMT2AKDM4ETP53
SCHEMBL4850475 0.82 F2RL3 (0.38) F2RL3MEN1KMT2AKDM4ETP53
SCHEMBL4846364 0.82 F2RL3 (0.38) F2RL3MEN1KMT2AKDM4ETP53
SCHEMBL4850224 0.80 ERBB2 (0.42) F2RL3MEN1KMT2AKDM4EGAA
SCHEMBL4843920 0.80 PPARG (0.44) F2RL3KDM4EALDH1A1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 F2RL3 4515/4885MEN1 3268/4885KMT2A 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.